Gabelli Funds’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.17M | Sell |
1,875
-322
| -15% | -$219K | 0.01% | 884 |
|
|
2026
Q1 | $1.7M | Buy |
2,197
+358
| +19% | +$274K | 0.01% | 788 |
|
|
2025
Q4 | $1.42M | Sell |
1,839
-27
| -1% | -$18.3K | 0.01% | 825 |
|
|
2025
Q3 | $1.05M | Buy |
1,866
+3
| +0.2% | +$1.7K | 0.01% | 910 |
|
|
2025
Q2 | $978K | Buy |
1,863
+55
| +3% | +$30.7K | 0.01% | 904 |
|
|
2025
Q1 | $1.15M | Sell |
1,808
-93
| -5% | -$64K | 0.01% | 758 |
|
|
2024
Q4 | $1.35M | Sell |
1,901
-42
| -2% | -$35.2K | 0.01% | 726 |
|
|
2024
Q3 | $2.04M | Buy |
1,943
+50
| +3% | +$55.6K | 0.01% | 651 |
|
|
2024
Q2 | $1.99M | Buy |
1,893
+34
| +2% | +$33K | 0.02% | 660 |
|
|
2024
Q1 | $1.79M | Buy |
1,859
+54
| +3% | +$51.3K | 0.01% | 686 |
|
|
2023
Q4 | $1.59M | Buy |
1,805
+255
| +16% | +$210K | 0.01% | 700 |
|
|
2023
Q3 | $1.28M | Hold |
1,550
| – | – | 0.01% | 747 |
|
|
2023
Q2 | $1.11M | Hold |
1,550
| – | – | 0.01% | 776 |
|
|
2023
Q1 | $1.27M | Hold |
1,550
| – | – | 0.01% | 750 |
|
|
2022
Q4 | $1.12M | Hold |
1,550
| – | – | 0.01% | 783 |
|
|
2022
Q3 | $1.07M | Hold |
1,550
| – | – | 0.01% | 808 |
|
|
2022
Q2 | $916K | Sell |
1,550
-282
| -15% | -$183K | 0.01% | 874 |
|
|
2022
Q1 | $1.28M | Sell |
1,832
-6,400
| -78% | -$4.05M | 0.01% | 828 |
|
|
2021
Q4 | $5.2M | Sell |
8,232
-400
| -5% | -$246K | 0.03% | 490 |
|
|
2021
Q3 | $5.22M | Sell |
8,632
-400
| -4% | -$248K | 0.03% | 488 |
|
|
2021
Q2 | $5.04M | Buy |
9,032
+5
| +0.1% | +$2.53K | 0.03% | 518 |
|
|
2021
Q1 | $4.27M | Buy |
9,027
+7,282
| +417% | +$3.55M | 0.03% | 543 |
|
|
2020
Q4 | $843K | Hold |
1,745
| – | – | 0.01% | 908 |
|
|
2020
Q3 | $977K | Sell |
1,745
-25
| -1% | -$15.2K | 0.01% | 828 |
|
|
2020
Q2 | $1.1M | Sell |
1,770
-155
| -8% | -$88K | 0.01% | 782 |
|
|
2020
Q1 | $940K | Buy |
1,925
+325
| +20% | +$134K | 0.01% | 794 |
|
|
2019
Q4 | $601K | Sell |
1,600
-500
| -24% | -$168K | ﹤0.01% | 918 |
|
|
2019
Q3 | $583K | Hold |
2,100
| – | – | ﹤0.01% | 937 |
|
|
2019
Q2 | $657K | Hold |
2,100
| – | – | ﹤0.01% | 952 |
|
|
2019
Q1 | $862K | Hold |
2,100
| – | – | 0.01% | 905 |
|
|
2018
Q4 | $784K | Sell |
2,100
-400
| -16% | -$146K | 0.01% | 901 |
|
|
2018
Q3 | $1.01M | Hold |
2,500
| – | – | 0.01% | 900 |
|
|
2018
Q2 | $862K | Buy |
2,500
+700
| +39% | +$219K | 0.01% | 936 |
|
|
2018
Q1 | $620K | Buy |
1,800
+800
| +80% | +$278K | ﹤0.01% | 971 |
|
|
2017
Q4 | $376K | Sell |
1,000
-5,800
| -85% | -$2.35M | ﹤0.01% | 1029 |
|
|
2017
Q3 | $3.04M | Hold |
6,800
| – | – | 0.02% | 687 |
|
|
2017
Q2 | $3.34M | Hold |
6,800
| – | – | 0.02% | 658 |
|
|
2017
Q1 | $2.63M | Buy |
6,800
+800
| +13% | +$297K | 0.02% | 711 |
|
|
2016
Q4 | $2.2M | Hold |
6,000
| – | – | 0.01% | 760 |
|
|
2016
Q3 | $2.41M | Hold |
6,000
| – | – | 0.01% | 736 |
|
|
2016
Q2 | $2.1M | Buy |
6,000
+1,300
| +28% | +$501K | 0.01% | 775 |
|
|
2016
Q1 | $1.69M | Sell |
4,700
-300
| -6% | -$124K | 0.01% | 796 |
|
|
2015
Q4 | $2.71M | Sell |
5,000
-500
| -9% | -$271K | 0.02% | 694 |
|
|
2015
Q3 | $2.56M | Sell |
5,500
-200
| -4% | -$107K | 0.02% | 706 |
|
|
2015
Q2 | $2.91M | Hold |
5,700
| – | – | 0.02% | 710 |
|
|
2015
Q1 | $2.57M | Sell |
5,700
-1,200
| -17% | -$509K | 0.01% | 731 |
|
|
2014
Q4 | $2.83M | Sell |
6,900
-1,100
| -14% | -$433K | 0.01% | 714 |
|
|
2014
Q3 | $2.88M | Hold |
8,000
| – | – | 0.01% | 718 |
|
|
2014
Q2 | $2.26M | Buy |
+8,000
| New | +$2.37M | 0.01% | 760 |
|
Other funds holding REGN
Gabelli Funds's REGN Position: Q2 2026 in Review
Gabelli Funds reduced its Regeneron Pharmaceuticals (REGN) stake by 15% in Q2 2026, selling an estimated $219K and leaving 1,875 shares worth $1.17M. The position accounts for 0.01% of the portfolio, ranked #884.
Gabelli Funds first reported a position in REGN in Q2 2014 and has held it in 49 quarters since. The position peaked at $5.22M in Q3 2021. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- Gabelli Funds held 1,875 shares of Regeneron Pharmaceuticals worth $1.17M as of Q2 2026.
- Gabelli Funds sold 322 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $219K.
- Regeneron Pharmaceuticals made up 0.01% of Gabelli Funds's portfolio in Q2 2026, its #884 holding.
- Gabelli Funds first reported a position in Regeneron Pharmaceuticals in Q2 2014 and has held it in 49 quarters since.
- Gabelli Funds's Regeneron Pharmaceuticals position peaked at $5.22M in Q3 2021.
- 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on Gabelli Funds's 13F filing for Q2 2026, filed 12 Aug 2026.